Drug management

Drug pricing & markets, value-based pricing, cost control, real-world evidence for safety and effectiveness

Viewpoint
Maggie Alston
Bruce Pyenson
They can work, but pharma will need to master the intricacies of adherence metrics, real-world outcomes, and sampling.
Medication Management
Thomas Reinke
Pharma and Trump administration officials decry them as backroom deals. But payers and PBMs say rebates are an important negotiating tool with drugmakers. Take it away and drug expenditure will go up even faster.
Ed Silverman
With accumulators, the value of any copay assistance cards or coupons does not count toward out-of-pocket medicine costs that are applied toward deductibles. It’s a cost-shifting tool that’s facing pushback from patients, providers, and others saying that accumulators will hurt public health.
Medication Management
Thomas Reinke
Next month, the Sanofi and Regeneron product is expected to become the fourth monoclonal antibody approved as a treatment for severe asthma.
Seeds of Innovation
Joseph Burns
Companies that negotiate for better prices on specialty drugs without the incentive of discounts and rebates.
Richard Mark Kirkner
It is finally starting to happen. The first gene therapy to treat an inherited disease is out of the gate. But my, that price tag: $850,000. Many more gene therapies are on their way. How can they be priced to hit the sweet spot of affordability, access, and innovation? Outcomes-based pricing doesn’t really do the trick.
Viewpoint
Bruce Pyenson
Gabriela Dieguez
Katherine Simon
Andrew Bochner
Despite standardization, advocates for various industries and certain patient needs continue to propose changes in coverage rules. Much of the advocacy is occurring at the state level with a focus on pharmaceutical coverage, such as equalizing cost sharing between oral and infused oncology drugs or setting limits on cost sharing for prescriptions.
Medication Management
Thomas Reinke
Aimovig and other drugs targeting the CGRP neuropeptide aim to prevent migraines in a whole new way. But Aimovig’s cost may mean an obstacle course of prior authorization and step therapy.